Literature DB >> 21980627

Clusterin as a potential marker in distinguishing cervical neoplasia.

Ilambarthi Lokamani1, Mee-Lee Looi, Siti Aishah Md Ali, Ahmad Zailani Hatta Mohd Dali, Rahman Jamal.   

Abstract

OBJECTIVE: To assess the immunoexpression of clusterin (CLU) in the progression of cervical neoplasia. STUDY
DESIGN: A total of 127 paraffin sections of cervical tissue consisting of normal cervical tissue, cervical intraepithelial neoplasia (CIN) lesions, cervical squamous cell carcinomas (SCCs), and adenocarcinoma of the cervix were examined by immunohistochemistry. The findings were evaluated in relation to clinicopathologic factors including grade of differentiation and lymph node involvement.
RESULTS: Immunopositivity of CLU was found in the cytoplasm of dysplastic cells, SCCs, and normal epithelium of the endocervical gland. There was negative expression in adenocarcinoma. High expression of CLU was found in CIN 3 compared to CIN 1 and CIN 2. The immunoreactivity of CLU was found in 95% of SCCs. The staining was positive in the upper 2/3 layers of the dysplastic epithelium for CIN 3 and showed a cluster pattern in cervical SCCs. There was no significant correlation between CLU immunoreactivity and lymph node involvement, as well as grade of differentiation.
CONCLUSION: The overexpression of CLU in various stages of cervical lesions may serve as a potential marker to distinguish cervical neoplasia with borderline morphology features.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21980627

Source DB:  PubMed          Journal:  Anal Quant Cytol Histol        ISSN: 0884-6812            Impact factor:   0.302


  3 in total

1.  Effects of down-regulation of clusterin by small interference RNA on human acute myeloid leukemia cells.

Authors:  Xiaoli Wang; Ruidong Liu; Yanxia Wang; Hengjuan Cai; Lei Zhang
Journal:  Int J Clin Exp Med       Date:  2015-11-15

2.  Clusterin role in hepatocellular carcinoma patients treated with oxaliplatin.

Authors:  Xiumei Wang; Yongqiang Liu; Qiong Qin; Ti Zheng
Journal:  Biosci Rep       Date:  2020-02-28       Impact factor: 3.840

3.  Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation.

Authors:  Yong Tang; Fenghua Liu; Chunning Zheng; Shaochuan Sun; Yingsheng Jiang
Journal:  J Exp Clin Cancer Res       Date:  2012-09-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.